

Product Name	: Volasertib
Synonyms	: BI 6727;BI-6727;BI6727
Cat No.	: M15871
CAS Number	: 755038-65-4
Molecular Formula	: C ₃₄ H ₅₀ N ₈ O ₃
Formula Weight	: 618.81
Chemical Name	: Benzamide, N-[trans-4-[4-(cyclopropylmethyl)-1-piperazinyl]cyclohexyl]-4-[[[(7R)-7-ethyl-5,6,7,8-tetrahydro-5-methyl-8-(1-methylethyl)-6-oxo-2-pteridiny]amino]-3-methoxy-
Description	Volasertib (BI 6727) is a potent, selective Polo-like kinase (PLK) inhibitor with IC₅₀ of 0.87, 5 and 56 nM for PLK1, 2 and 3, respectively; displays no inhibitory activity against a panel of >50 other kinases; inhibits proliferation of multiple cell lines derived from various cancer tissues, including HCT116 (EC₅₀=23 nM) and NCI-H460 (EC₅₀=21 nM), BRO (EC₅₀=11 nM), and hematopoietic cancer cell HL-60 (EC₅₀=32 nM); demonstrates marked antitumor activity in multiple cancer models, including a model of taxane-resistant colorectal cancer. Blood Cancer Phase 3 Clinical
Pathway	: Cell Cycle/DNA Damage
Target	: PLK
Receptor	: PLK1
Solubility	: 10 mM in DMSO
SMILES	: <chem>O=C(N[C@@H]1CC[C@@H](N2CCN(CC3CC3)CC2)CC1)C4=CC=C(NC(N=C5N(C(C)C)[C@@H]6CC)=NC=C5N(C)C6=O)C(OC)=C4</chem>
Storage	: (-20°C)
Stability	: ≥ 2 years
Reference	:

1. Rudolph D, et al. Clin Cancer Res. 2009 May 1;15(9):3094-102. | 2. Grinshtein N, et al. Cancer Res. 2011 Feb 15;71(4):1385-95. | 3. Schffski P, et al. Eur J Cancer. 2012 Jan;48(2):179-86. | 4. Sanhaji M, et al. Cell Cycle. 2012 Feb 1;11(3):543-53.